IAS 2023, the 12th IAS Conference on HIV Science, Brisbane, Australia, and virtually, 23-26 July 2023

项目摘要 联合国艾滋病规划署估计，2021年艾滋病毒发病率为150万新感染者，而2020年的目标是 该年全球感染人数将低于50万人。按照这个速度，艾滋病毒的反应大大偏离了目标 实现到2030年结束作为全球公共卫生威胁的大流行的目标。 新冠肺炎大流行严重影响了艾滋病毒的应对，因为它造成了对 艾滋病毒应对、艾滋病毒检测和预防。此外，随着世卫组织宣布猴痘为公众 国际关注的卫生紧急情况，而这一新的出现目前在 男男性行为者，一个对艾滋病毒负担非常高的社区，目前有三个并发 大流行病正在挑战人类健康和福祉、卫生系统和脆弱的公共卫生。 世界各地的基础设施。《国际会计准则2023》必须在更广泛的大流行防备的背景下解决艾滋病毒科学问题 以及新冠肺炎和猴痘对艾滋病毒携带者和健康的影响 系统和提供商。疫苗科学将是突出的，以及抗病毒药物及其相互作用 所有这三种病毒大流行。在发展中加快基础科学和临床科学创新 以及以人为中心的精准医学在艾滋病毒治疗中的应用，减少艾滋病毒传播，疫苗， 发病机制、合并感染和寻找治疗方法将在2023年国际会计准则会议上占据突出地位。 《国际会计准则2023》的具体目标将是： 1.推进执行研究中的跨学科协作，以减少艾滋病毒传播和改善 所有生命阶段的治疗结果，特别注重将研究成果转化为政策 通过简化的低收入和中等收入国家和主要国家实用指南进行实践 人口。 2.加强艾滋病毒预防研究，提高生物医学、行为和结构的成本效益 干预措施，特别注重了解执行挑战、克服体制障碍 并在艾滋病毒预防实践和方案中复制成功。 3.解决艾滋病毒脆弱性、艾滋病毒负担的决定因素以及关键和低收入人群的不良临床结果 边缘化人口，包括减少耻辱和歧视并改善机会的干预措施 将抗逆转录病毒疗法用于预防和治疗，特别侧重于原住民和土著 社区和以人为中心的方法。 4.重新参与和振兴社区、临床、社会和政治努力，以解决未得到满足的艾滋病毒需求和 加强新冠肺炎时代亚太地区艾滋病政策，特别关注需求 被边缘化的第一民族和土著社区。 科学计划将沿着五个科学轨道构建：基础科学、临床科学、流行病学 和预防科学；社会和行为科学；实施科学、经济学、系统和 协同效应。下文描述了每个专题领域要处理的主题。科学计划是 由多学科国际组织委员会制定，其成员是根据基地挑选的 科学、政策和实施方面的专门知识，有意义地参与和代表关键和 受影响人口、民间社会和/或青年以及地域和性别多样性是关键 能力和属性确保所有级别的多样性。将在全体会议上强调贯穿各领域的问题 演讲也将科学与社区和领导力的观点联系起来。此外，桥接会话 旨在跨越不同的主题领域，提供多学科、多领域的机会 视角对话，通常使用交互格式。 在第24届国际艾滋病大会--2022年艾滋病混合格式取得成功的基础上，《2023年国际会计准则》将 面对面和虚拟地举行，提供了许多讨论、辩论和互联的机会 在面对面和虚拟演讲者和观众之间。预计将有6000名艾滋病毒科学家出席， 临床医生、政策制定者和计划实施者以及公民社会、社区和私营部门 代表(4 500人亲自出席，1 500人在线)。2023年国际会计准则将提供奖学金，以确保 研究人员、社区活动家和民间社会代表的参与，特别是来自 资源有限的环境和代表性不足的社区。在最佳做法的指导下，混合格式将 最大限度地为各级所有利益攸关方提供包容性会议体验。

Project Summary IN 2021 UNAIDS estimated the HIV incidence to have been 1.5 million new infections, while the 2020 target was set to be under 500,000 global infections for that year. At this rate, the HIV response is sharply off target to achieve the goal of an end to the pandemic as the global public health threat by 2030. The COVID-19 pandemic has severely affected the HIV response as it has caused consequential disruption in the HIV response, HIV testing and prevention. Furthermore, with WHO’s declaration of Monkeypox as a public health emergency of international concern, and this new emergence currently occurring overwhelmingly among men who have sex with men, a community with a very high burden for HIV, there are currently three concurrent pandemics underway challenging human health and wellbeing, health systems, and fragile public health infrastructures worldwide. IAS 2023 must address HIV science in the context of a wider pandemic preparedness and with a view toward the impacts of COVID-19 and Monkeypox on persons living with HIV, and on health systems and providers. Vaccine science will be prominent, as well as antiviral agents and their interactions for all three of these viral pandemics. Accelerate basic science and clinical science innovation in the development and application of person-centered precision medicine for HIV treatment, reducing HIV transmission, vaccines, pathogenesis, co-infections, and the search for a cure will feature prominently at IAS 2023. Specific aims of IAS 2023 will be to: 1. Advance inter-disciplinary collaboration in implementation research to reduce HIV transmission and improve treatment outcomes across all life-stages with a special focus on translating research outcomes into policy and practice through simplified practical guidelines for low- and middle-income countries and key populations. 2. Strengthen HIV prevention research to improve cost-effective biomedical, behavioral and structural interventions with a special focus on understanding implementation challenges, overcoming system barriers and replicating successes in HIV prevention practice and programs. 3. Address HIV vulnerability, determinants of HIV burdens and poor clinical outcomes among key and marginalized populations, including interventions to reduce stigma and discrimination and improve access and uptake of ART for prevention and treatment with a special focus on First Nations and Indigenous communities and on person-centered approaches. 4. Re-engage and reenergize community, clinical, social and political efforts to address unmet HIV needs and strengthen HIV policy in the Asia-Pacific region in the COVID-19 era, paying special attention to the needs of marginalized First Nations and Indigenous communities. The scientific program will be structured along five scientific tracks: basic science; clinical science; epidemiology & prevention science; social and behavioural sciences; implementation science, economics, systems and synergies. Topics to be addressed in each thematic area are described below. The scientific program is developed by a multi-disciplinary international Organizing Committee whose members are selected on the bases of scientific, policy and implementation expertise, meaningful engagement and representation of key and affected populations, of civil society and / or young people and geographic and gender diversity as key competencies and attributes ensuring diversity at all levels. Cross-cutting aspects will be highlighted in plenary talks that also connect the science with community and leadership perspectives. Additionally, bridging sessions are designed to cut across the different thematic areas to provide opportunities for multi-disciplinary, multi- perspective dialogues, often using interactive formats. Building on the success of the 24th International AIDS Conference - AIDS 2022 in hybrid format, IAS 2023 will be held in-person and virtually, providing many opportunities for discussions, debates and interconnection between the in-person and virtual speakers and audiences. Expected attendance is 6,000 HIV scientists, clinicians, policy makers, and program implementers as well as civil society, community and private sector representatives (4,500 in person and 1,500 online). IAS 2023 will provide scholarships to ensure the full participation of researchers, community activists and civil society representatives, especially those from resource-limited settings and underrepresented communities. Guided by best practices, the hybrid format will maximize inclusive conference experiences for all stakeholders at all levels.